Advanced search
Publication Cover
Cancer Investigation Volume 33, 2015 - Issue 8
Submit an article Journal homepage
873
Views
10
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma

Hideharu BesshoLaboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore;Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore;Department of Urology, Kitasato University School of Medicine, Kanagawa, JapanCorrespondence[email protected]
,
Bernice WongLaboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore;Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore
,
Dachuan HuangLaboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore;Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore
,
Jing TanLaboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore;Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore
,
Choon Kiat OngLaboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore;Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore
,
Masatsugu IwamuraDepartment of Urology, Kitasato University School of Medicine, Kanagawa, Japan
,
Stefan HartRoche Pharma Research & Early Development, Translational Medicine Hub, Singapore, Singapore
,
Markus DanglRoche Pharma Research & Early Development, Translational Medicine Hub, Singapore, Singapore
,
Markus ThomasRoche Diagnostics GmbH, Penzberg, Germany
&
Bin Tean TehLaboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore;Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore;Cancer Science Institute of Singapore, National University of Singapore, Singapore
 show all
Pages 378-386 | Received 05 Jun 2014, Accepted 25 Apr 2015, Published online: 26 Jun 2015
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

ABSTRACT

The blockade of VEGF pathway has been clinically validated as an initial treatment for renal cell carcinoma (RCC). Angiopoietin-2 (Ang-2) has been indicated as a key regulator for angiogenesis escape. The effect of a novel bispecific antibody (A2V CrossMab) against both Ang-2 and VEGF was investigated in comparison with either factor. A2V CrossMab significantly reduced tumor volume, vessel density, and interstitial fluid pressure compared to either monotherapy of anti-VEGF or anti-Ang-2. Host-derived angiogenesis-related genes have been significantly down-regulated in A2V CrossMab group. These data demonstrate that A2V CrossMab has additive anti-tumor effect for the treatment of RCC.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,193.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.